Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Market Cap & Net Worth: Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (LGNZZ)
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (PINK:LGNZZ) has a market capitalization of $1.37K ($1.37K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #33382 globally and #10904 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's stock price $0.14 by its total outstanding shares 9768 (9.77K).
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt Market Cap History: 2015 to 2025
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's market capitalization history from 2015 to 2025. Data shows growth from $341.88 to $1.37K (13.58% CAGR).
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $341.88 | $71.91 Million | $229.82 Million | 0.00x | 0.00x |
| 2016 | $138.71 | $108.97 Million | -$2.37 Million | 0.00x | N/A |
| 2017 | $126.98 | $141.10 Million | $12.56 Million | 0.00x | 0.00x |
| 2018 | $1.37K | $251.45 Million | $143.32 Million | 0.00x | 0.00x |
| 2019 | $1.95K | $120.28 Million | $629.30 Million | 0.00x | 0.00x |
| 2020 | $1.66K | $186.42 Million | -$2.98 Million | 0.00x | N/A |
| 2021 | $1.38K | $241.54 Million | $57.14 Million | 0.00x | 0.00x |
| 2022 | $1.47K | $196.25 Million | -$33.36 Million | 0.00x | N/A |
| 2023 | $1.27K | $131.31 Million | $52.15 Million | 0.00x | 0.00x |
| 2024 | $1.27K | $167.13 Million | $9.07 Million | 0.00x | 0.00x |
Competitor Companies of LGNZZ by Market Capitalization
Companies near Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt in the global market cap rankings as of March 18, 2026.
Key companies related to Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt by market ranking:
- Olivut Resources Ltd (PINK:OLVRF): Ranked #33373 globally with a market cap of $2.70 Million USD.
- T.R.V. Rubber Products PCL (BK:TRV): Ranked #33374 globally with a market cap of $2.70 Million USD ( ฿93.69 Million THB).
- Nusa Palapa Gemilang PT Tbk (JK:NPGF): Ranked #33383 globally with a market cap of $2.70 Million USD ( Rp43.86 Billion IDR).
- Real Good Food Company Inc (NASDAQ:RGF): Ranked #33384 globally with a market cap of $2.69 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #33373 | Olivut Resources Ltd | PINK:OLVRF | $2.70 Million | $0.04 |
| #33374 | T.R.V. Rubber Products PCL | BK:TRV | $2.70 Million | ฿1.71 |
| #33383 | Nusa Palapa Gemilang PT Tbk | JK:NPGF | $2.70 Million | Rp68.00 |
| #33384 | Real Good Food Company Inc | NASDAQ:RGF | $2.69 Million | $0.15 |
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt Historical Marketcap From 2015 to 2025
Between 2015 and today, Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's market cap moved from $341.88 to $ 1.37K, with a yearly change of 13.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.37K | +7.69% |
| 2024 | $1.27K | 0.00% |
| 2023 | $1.27K | -13.33% |
| 2022 | $1.47K | +6.38% |
| 2021 | $1.38K | -17.06% |
| 2020 | $1.66K | -15.00% |
| 2019 | $1.95K | +42.86% |
| 2018 | $1.37K | +976.92% |
| 2017 | $126.98 | -8.45% |
| 2016 | $138.71 | -59.43% |
| 2015 | $341.88 | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37K USD |
| MoneyControl | $1.37K USD |
| MarketWatch | $1.37K USD |
| marketcap.company | $1.37K USD |
| Reuters | $1.37K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.